GB1113851A - Decoyinine derivatives - Google Patents

Decoyinine derivatives

Info

Publication number
GB1113851A
GB1113851A GB1833965A GB1833965A GB1113851A GB 1113851 A GB1113851 A GB 1113851A GB 1833965 A GB1833965 A GB 1833965A GB 1833965 A GB1833965 A GB 1833965A GB 1113851 A GB1113851 A GB 1113851A
Authority
GB
United Kingdom
Prior art keywords
inclusive
carbon atoms
formula
dihydrodecoyinine
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1833965A
Inventor
Clarence De Boer
Alma Dietz
Le Roy Emanuel Johnson
Thomas Eugene Eble
Herman Hoeksema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to GB1833965A priority Critical patent/GB1113851A/en
Publication of GB1113851A publication Critical patent/GB1113851A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Abstract

Triacyl derivatives of the antibiotic decoyinine having the formula <FORM:1113851/C2/1> wherein R is selected from hydrocarbon carboxylic acyl of from 9 to 12 carbon atoms inclusive, halo-, nitro-, hydroxy-, amino-, cyano-, thiocyano-and lower-alkoxy (C1 to C6 inclusive) -substituted hydrocarbon carboxylic acid acyl of from 2 to 12 carbon atoms inclusive and lower-alkoxy (C1 to C6 inclusive) carbonyl, are prepared by a process similar to that described in Specification 985,162 for preparing the decoyinine triacylates disclosed therein. Triacyl derivatives of the above formula may be hydrogenated (see also Specification 985,162) to produce dihydrodecoyinine triacylates of the formula <FORM:1113851/C2/2> wherein R is as above defined and deoxydihydrodecoyinine diacylates of the formula <FORM:1113851/C2/3> wherein R is as above defined. Dihydrodecoyinine and deoxydihydrodecoyinine (prepared by the deacylation of dihydrodecoyinine triacylates and dihydrodecoyinine diacylates and separation of the resulting mixture) can be acylated to produce dihydrodecoyinine tetra- and pentaacylates of the formula <FORM:1113851/C2/4> and deoxydihydrodecoyinine tri- and tetraacylates of the formula <FORM:1113851/C2/5> wherein R is selected from hydrocarbon carboxylic acid acyl of from 2 to 12 carbon atoms, inclusive; halo-, nitro-, hydroxy-, amino-, cyano-, thiocyano-, and lower alkoxy-substituted hydrocarbon carboxylic acid acyl of from 2 to 12 carbon atoms inclusive; and lower alkoxy (C1 to C6 inclusive) carbonyl; and R1 is selected from hydrogen and hydrocarbon carboxylic acid acyl of from 2 to 12 carbon atoms inclusive; halo-, nitro-, hydroxy-, amino-, cyano-, thiocyano-, and lower alkoxy-substituted hydrocarbon carboxylic acid acyl of from 2 to 12 carbon atoms inclusive; and lower alkoxy (C1 to C6 inclusive) carbonyl.ALSO:Acylates of the antibiotic decoyinine and its derivatives dehydrodecoyinine and deoxydihydrodecoyinine (see Division C2) comprise the active ingredients of pharmaceutical compositions. The compositions contain a pharmaceutically acceptable carrier and may be administered orally, parenterally or applied topically in the form of tablets, effervescent tablets, powders, granules, capsules, solutions and suspensions (these may be sterile and include aqueous suspensions and oil suspensions especially those containing edible oil) ointments, creams, water-oil emulsions, lotions and baugies. The compositions have bactericidal activity and may also contain sulpha compounds (e.g. sulphadiazine, sulphamerazine, sulphanilamide, sulphamethazine, sulphacetamide and sulphamethylthiadiazole); other antibiotics (e.g. tetracycline, oxytetracyline, chlotetracycline, penicillins, novobiocin, neomycin, psicofuranine, erythromycin, streptomycin, bacitracin, polymyxin, chloramphenical, kanamycin, nystatin and streptozotocin); vitamins (e.g. thiamine, riboflavin, ascorbic acid, niacinamide, pyridoxine, pantothenic acid or pantothenate salts, vitamin B1Z and folic acid); corticoids (e.g. cortisone, hydrocortisone, prednisone and prednisolone, including esters thereof, e.g. the acetate, cyclo pentylpropionate, succinate and the sodium salt, and the fluoro, methyl, and hydroxy analogues thereof such as 6a -fluorohydrocortisone, 16 - hydroxy - 9a - fluorohydrocortisone and 16 - methyl - 9a - fluoroprednisolone, and the esters thereof).
GB1833965A 1965-05-29 1965-05-29 Decoyinine derivatives Expired GB1113851A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1833965A GB1113851A (en) 1965-05-29 1965-05-29 Decoyinine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1833965A GB1113851A (en) 1965-05-29 1965-05-29 Decoyinine derivatives

Publications (1)

Publication Number Publication Date
GB1113851A true GB1113851A (en) 1968-05-15

Family

ID=10110772

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1833965A Expired GB1113851A (en) 1965-05-29 1965-05-29 Decoyinine derivatives

Country Status (1)

Country Link
GB (1) GB1113851A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
US5378693A (en) * 1988-11-15 1995-01-03 Merrell Dow Pharmaceuticals Inc. 2'-halomethylidene cytidine, uridine and guanosine compounds and their pharmaceutical compositions
US5521162A (en) * 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US5595979A (en) * 1994-07-11 1997-01-21 Merrell Pharmaceuticals Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5607925A (en) * 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
US5616702A (en) * 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521162A (en) * 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
US5378693A (en) * 1988-11-15 1995-01-03 Merrell Dow Pharmaceuticals Inc. 2'-halomethylidene cytidine, uridine and guanosine compounds and their pharmaceutical compositions
US5607925A (en) * 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
US5616702A (en) * 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
US5792841A (en) * 1988-11-15 1998-08-11 Merrell Pharmaceuticals Inc. 2'-halomethylidene, 2'-ethenylidene and 2'-ethynl cytidine, uridine and guanosine derivatives
US5977325A (en) * 1988-11-15 1999-11-02 Merrell Pharmaceuticals Inc. 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
US5595979A (en) * 1994-07-11 1997-01-21 Merrell Pharmaceuticals Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy

Similar Documents

Publication Publication Date Title
CN1133422C (en) Topical application of combination of benzoyl peroxide and second active ingredient
EP0091645B1 (en) Derivatives of amides of carboxylic acids in which the n atom is substituted by a glycosyl radical, method for their preparation and their use to influence the immunogenic system
KR890009383A (en) Fatty acid compounds
GB1113851A (en) Decoyinine derivatives
US5149694A (en) Combination of tobramycin and dexamethasone for topical ophthalmic use
IE32705B1 (en) Novel alpha-carboline derivatives,the preparation thereof and compositions containing the same
HUT49365A (en) Process for producing 3&#39;-deamino-4&#39;-deoxy-4&#39;-aminoanthracycline derivatives and pharmaceutical compositions comprising such active ingredient
US5045533A (en) Retinoic esters of antibiotics and pharmaceutical and cosmetic compositions containing them
GR3033459T3 (en) Novel vitamin d derivatives with c-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments
DE69333723T2 (en) PHARMACEUTICAL PREPARATION BASED ON RHAMNOLIPIDE AGAINST DERMATOLOGICAL DISEASES
EP0177581A4 (en) Compositions used for hair growth.
US5149693A (en) Combination of tobramycin and fluorometholone for topical ophthalmic use
US3639636A (en) Method of lowering serum cholesterol
GB1470355A (en) Pharmaceutical compositions
DE3116029C2 (en)
US3375165A (en) Fusidic acid salts of tetracycline bases and therapy
GB887303A (en) Improvements in or relating to therapeutic compositions comprising novobiocin
EP0664704B1 (en) Use of dopamine agonists to activate gamma-interferon production
Valeriote et al. Potentiation of cytotoxicity of anticancer agents by several different polyene antibiotics
US2403473A (en) Therapeutic compositions
EP0115001B1 (en) Stable aminoglycoside-penicillin injection formulation
US3681323A (en) 6,9-oxygen bridged erythromycin derivatives
EP1212346A1 (en) Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds
GB709376A (en) Improvements in or relating to antibiotic pharmaceutical compositions
GB992276A (en) Compounds related to fusidic acid and dihydrofusidic acid